Dr. Gregory A. Ledger, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 214
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Indiana University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
MO license 105722
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mercy Hospital Springfield Springfield, MO
Medical groups
- Mercy Clinic Springfield Communities (1,120 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 214
- Services billed
- 558
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 431 | 331 |
| Established patient office or other outpatient visit, 20-29 minutes | 39 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 32 | 15 |
| Ultrasound scan of head and neck soft tissue | 14 | 14 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 13 | 11 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 12 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Springfield, MO | 236 |
| Testosterone Other prescribers in Springfield, MO | 58 |
| Testosterone Cypionate Other prescribers in Springfield, MO | 43 |
| Metformin Hcl Other prescribers in Springfield, MO | 41 |
| Methimazole Other prescribers in Springfield, MO | 35 |
| Amlodipine Besylate Other prescribers in Springfield, MO | 29 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Springfield, MO | 28 |
| Prednisone Other prescribers in Springfield, MO | 26 |
| Synthroid (levothyroxine sodium) Other prescribers in Springfield, MO | 24 |
| Glimepiride Other prescribers in Springfield, MO | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $57.28 in total to this clinician.
| Pfizer Inc. | $48.58 |
|---|---|
| Beta Bionics, Inc. | $8.70 |
| Food and Beverage | $57.28 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $75,993 in research payments for these studies, mostly to the institutions running them.
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.